Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

15 Jan 2021

Abstract excerpt

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. These NTRK gene fusions are oncogenic drivers found in most tumour types at a low frequency (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., secretory carcinoma of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Tumor Research and Treatment
Share to Lymphoma Diagnosis and Treatment
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33467570
DOI: 10.3390/curroncol28010053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in AdultsPMID 33467570Read ↗

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric PatientsSemantic proximity Read ↗

Testing algorithm for identification of patients with TRK fusion cancerSemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaSemantic proximity Read ↗

NTRK gene fusion testing and management in lung cancerSemantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationSemantic proximity Read ↗

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid CarcinomasSemantic proximity Read ↗

[Diagnosis and therapy of tumors with NTRK gene fusion].Semantic proximity Read ↗

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in ChinaSemantic proximity Read ↗

Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites.Semantic proximity Read ↗

NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.